Note 13 - Concentration of credit risk	6 Months Ended
Jun. 30, 2018
Notes
Note 13 - Concentration of credit risk	Note 13 - Concentration of credit risk The Company has a significant portion of its assets invested in G Farma entities. These investments include the notes receivable described in Note 9, the finance leases receivable described in Note 10, and the contractual interest in legal recovery described in Note 12. At June 30, 2018, 2018 and December 31, 2017, these assets represent 26% and 19% of the consolidated total assets of the Company, respectively. The Company closely monitors each investment quarterly based on known and inherent risks in our investments which include financial results, satisfying scheduled payments and compliance with financial covenants, adverse situations that may affect the borrower’s ability to repay, estimated value of underlying collateral and current economic conditions. No impairments or reserves are recorded at June 30, 2018 or December 31, 2017 for these investments.

Note 13 - Concentration of credit risk

6 Months Ended

Jun. 30, 2018

Note 13 - Concentration of credit risk

The Company has a significant portion of its assets invested in G Farma entities. These investments include the notes receivable described in Note 9, the finance leases receivable described in Note 10, and the contractual interest in legal recovery described in Note 12. At June 30, 2018, 2018 and December 31, 2017, these assets represent 26% and 19% of the consolidated total assets of the Company, respectively.

The Company closely monitors each investment quarterly based on known and inherent risks in our investments which include financial results, satisfying scheduled payments and compliance with financial covenants, adverse situations that may affect the borrower’s ability to repay, estimated value of underlying collateral and current economic conditions. No impairments or reserves are recorded at June 30, 2018 or December 31, 2017 for these investments.